This inventor holds 5 USPTO granted patents. Top assignees: Daikin Industries, Ltd., Kyoto University, Adeka Argus Chemical Co., Ltd.. Active years: 1989-2008.
Location History:
- Kyoto, JP (1989 - 1994)
- Sakyo-ku, Kyoto-shi, Kyoto JP (2008)
Company Filing History:
2 out of 4,487 
2 out of 868 
1 out of 93 
Years Active: 1989-2008
Title: Tsutomu Kagiya: Innovator in Cancer Treatment
Introduction
Tsutomu Kagiya is a notable inventor based in Kyoto, Japan. He has made significant contributions to the field of cancer treatment through his innovative patents. With a total of 5 patents, Kagiya's work focuses on enhancing the efficacy and safety of cancer chemotherapy.
Latest Patents
One of Kagiya's latest patents is an ameliorant for chemical treatment of cancer. This invention discloses an ameliorating agent for cancer chemotherapy, which comprises a chromanol glycoside. The agent acts safely and effectively in small dosages to enhance the carcinostatic action of anti-cancer agents while repressing side effects associated with chemotherapy. Another significant patent involves fluorine-containing nitroimidazole compounds. This patent describes a 2-nitroimidazole compound that serves as a radiosensitizer, which is crucial in improving the effectiveness of cancer treatments.
Career Highlights
Throughout his career, Tsutomu Kagiya has worked with prominent companies, including Daikin Industries, Ltd. His innovative approach and dedication to research have positioned him as a key figure in the development of cancer treatment technologies.
Collaborations
Kagiya has collaborated with notable individuals in his field, including Mitsuyuki Abe and Seiichi Nishimoto. These collaborations have further enriched his research and contributed to the advancement of cancer treatment methodologies.
Conclusion
Tsutomu Kagiya's contributions to cancer treatment through his patents highlight his innovative spirit and commitment to improving patient outcomes. His work continues to influence the field of oncology and offers hope for more effective cancer therapies.